Clicky

Bionomics Limited(BNOX)

Description: Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


Keywords: Cancer Biopharmaceutical Clinical Medicine Drugs Monoclonal Antibodies Cancer Treatment Alzheimer's Disease Stem Cell Antineoplastic Drugs Central Nervous System Disorders Post Traumatic Stress Disorder Treatment Of Central Nervous System Disorders Anxiolytics Cognitive Impairment Camidanlumab Tesirine Milatuzumab Dipeptides Bnc 210 Bnc210 Nicotinic Antagonists

Home Page: www.bionomics.com.au

BNOX Technical Analysis

200 Greenhill Road
Eastwood, SA 5063
Australia
Phone: 61 8 8150 7400


Officers

Name Title
Dr. Errol B. De Souza Ph.D. Exec. Chairman
Mr. Adrian Hinton BEC, F.C.A. Acting Chief Financial Officer
Mr. Connor Bernstein M.Sc. VP of Strategy & Corp. Devel.
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Consultant Chief Medical Officer of Clinical Neuroscience
Ms. Suzanne Irwin B.Com., FCIS Company Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.3059
Price-to-Sales TTM: 8.4433
IPO Date: 2021-12-16
Fiscal Year End: June
Full Time Employees: 0
Back to stocks